Receptor-Mediated Targeted Delivery of Surface-ModifiedNanomedicine in Breast Cancer: Recent Update and Challenges

Abstract

Breast cancer therapeutic intervention continues to be ambiguous owing to the lack of strategies for targeted transport and receptor-mediated uptake of drugs by cancer cells. In addition to this, sporadic tumor microenvironment, prominent restrictions with conventional chemotherapy, and multidrug-resistant mechanisms of breast cancer cells possess a big challenge to even otherwise optimal and efficacious breast cancer treatment strategies. Surface-modified nanomedicines can expedite the cellular uptake and delivery of drug-loaded nanoparticulate constructs through binding with specific receptors overexpressed aberrantly on the tumor cell. The present review elucidates the interesting yet challenging concept of targeted delivery approaches by exploiting different types of nanoparticulate systems with multiple targeting ligands to target overexpressed receptors of breast cancer cells. The therapeutic efficacy of these novel approaches in preclinical models is also comprehensively discussed in this review. It is concluded from critical analysis of related literature that insight into the translational gap between laboratories and clinical settings would provide the possible future directions to plug the loopholes in the process of development of these receptor-targeted nanomedicines for the treatment of breast cancer.

Formulation of Piperine Nanoparticles: In Vitro Breast Cancer Cell Line and In Vivo Evaluation

“…In the modern era of the 21st century, breast cancer (BC) still remains a major health concern in women globally. This neoplastic disease is characterized by the uncontrolled cell division of cancerous cells in the breast tissue, leading to the development of a tumor mass [ 1 ]. At present, more than 1 million women are diagnosed with BC every year [ 2 ].…”

Surface-modified nanotherapeutics targeting atherosclerosis

“…Among the various hurdles, the first is the large-scale production of targeted nanoparticles as it faces continual issues such as multi-step preparation which poses challenges to the reproducibility of its preparation. [133][134][135] In the process of clinical translation, we also need to understand atherosclerosis is a long-term chronic disease. Long-term repeated intravenous administration is not ideal and is likely to result in poor compliance, yielding obstacles to impede the clinical translation.…”

Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update

“…However, ensuring a safe, targeted delivery mechanism to cancer cells while sparing healthy tissues remains a challenge and warrants further research ( Rizwanullah et al, 2021 ). Approaches such as viral vectors are being explored to improve cell type specificity ( Levy et al, 2020 ).…”